Barbara Sennino
Senior Vice President & Head of Early Development 3T Biosciences
Dr. Barbara Sennino is Senior Vice President and Head of Early Development at 3T Biosciences. She brings over 15 years of cancer immunotherapy experience across industry and academia, previously holding leadership roles at Turnstone Biologics, PACT Pharma, Five Prime Therapeutics, and Bavarian Nordic. Dr. Sennino earned her MSc in Biology from the University of Milan and a PhD in Biomedical Sciences from the University of Brescia, and she has authored numerous publications and patents related to T‑cell therapies.
Seminars
Join this workshop to move beyond the “AI buzzword” and confront the biological hurdles of antigen heterogeneity. As we pivot toward more complex engineering, this session addresses the critical uncertainty of target density: determining whether 20% or 80% cellular expression is the threshold for clinical success.
- Using machine learning to synthesize datasets to profile antigen prevalence across primary vs. metastatic tissues
- Identifying which novel targets are tumor-specific versus those with risky low-level expression in healthy tissues
- Deep-diving into the antigen expression level needed to trigger the action of a T-cell engager
- Developing AI algorithms that move beyond simple “positive/ negative” IHC scores to more predictive “probability of response” scores based on complex expression patterns
- Discussing how clinical trial failures can be fed back into AI models to refine the next generation of discovery
